Behdad Akbarpour
Internal Medicine · Irvine, CANPI 1760604979
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 991 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 48 manufacturers, the largest accounting for just 19.5% — the pattern of someone who eats at a lot of different presentations. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 991 payments — averaging $32.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Nestle Healthcare Nutrition Inc.$3K
- Novo Nordisk$3K
- Lilly USA, LLC$2K
- Amgen$2K
- Boehringer Ingelheim$2K
- plus $15K from 42 others
What the payments were for
- Travel & lodging$100%
- Food & beverage$32,496100%
- Education$290%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,535 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 36 | $64,380 |
| ZenpepLipase/Protease/Amylase | 11 | $36,706 |
| MounjaroTirzepatide | 19 | $24,994 |
| KerendiaFinerenone | 12 | $20,436 |
| Repatha SureclickEvolocumab | 16 | $19,272 |
| JardianceEmpagliflozin | 15 | $17,500 |
| Icosapent Ethyl | 35 | $14,804 |
| Tadalafil | 16 | $6,888 |
| Rosuvastatin Calcium | 57 | $935 |
| Testosterone Cypionate | 12 | $389 |
| Losartan Potassium | 36 | $325 |
| Tamsulosin Hcl | 25 | $274 |
| Metformin Hcl | 35 | $247 |
| Amlodipine Besylate | 24 | $235 |
| Atorvastatin Calcium | 19 | $143 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $2,783 | $64,38036 claims |
| Aimmune Therapeutics, Inc.Zenpep | $1,749 | $36,70611 claims |
| Lilly USA, LLCMounjaro | $1,901 | $24,99419 claims |
| BayerKerendia | $1,272 | $20,43612 claims |
| Boehringer IngelheimJardiance | $1,834 | $17,50015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Irvine
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.